Literature DB >> 6237922

Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.

R E Heikkila, L Manzino.   

Abstract

Two aryl 1,4-dialkylpiperazines (GBR 12909 and GBR 13098) and one aryl 1,4-dialkenylpiperazine (GBR 13069) were very potent inhibitors of [3H]dopamine uptake in vitro in tissue slices obtained from rat neostriatum (IC50 values between 40 and 51 nM). Each compound was considerably weaker as an inhibitor of [3H]norepinephrine uptake in tissue slices obtained from rat occipital cortex (IC50 values between 560 and 2600 nM). These compounds thus are relatively specific inhibitors of [3H]dopamine uptake in vitro. The three compounds caused ipsilateral circling in rats with unilateral lesions of the nigrostriatal pathway as well as increased locomotor activity in naive mice, both of which could be greatly attenuated by pretreatment of the rodents with the dopamine receptor antagonist haloperidol. It thus follows that the compounds have dopaminergic activity in vivo. Ex vivo experiments with GBR 13069 (drug administration in vivo, uptake in vitro) suggested that these compounds may have the same relative specificity as dopamine uptake blockers in vivo. These compounds should prove to be useful pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237922     DOI: 10.1016/0014-2999(84)90483-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  41 in total

1.  Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.

Authors:  Chunyang Jin; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.

Authors:  H Nissbrandt; G Engberg; E Pileblad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

5.  Possible existence of a presynaptic positive feedback mechanism enhancing dopamine transmission in the anterior cingulate cortex of the rat.

Authors:  M Beauregard; A Ferron; L Descarries
Journal:  Experientia       Date:  1989-09-15

6.  The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration.

Authors:  Jared W Young; Andrew K L Goey; Arpi Minassian; William Perry; Martin P Paulus; Mark A Geyer
Journal:  Pharmacol Biochem Behav       Date:  2010-04-02       Impact factor: 3.533

7.  Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice.

Authors:  Asma Khan; Loek A W de Jong; Mary E Kamenski; Kerin K Higa; Jacinta D Lucero; Jared W Young; M Margarita Behrens; Susan B Powell
Journal:  Neuroscience       Date:  2016-11-24       Impact factor: 3.590

8.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

9.  Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.

Authors:  C J Sun; J N Johannessen; W Gessner; I Namura; W Singhaniyom; A Brossi; C C Chiueh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior.

Authors:  Jared W Young; Andrew K L Goey; Arpi Minassian; William Perry; Martin P Paulus; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-12-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.